Related Experiment Video
Updated: Jun 29, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
2-Chloroadenosine and human prostate cancer cells.
I Bellezza1, A Tucci, A Minelli
1Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, via del Giochetto, 06123 Perugia, Italia.
Anti-Cancer Agents in Medicinal Chemistry
|October 16, 2008
Summary
2-Chloroadenosine, a less-studied analogue of cladribine, shows promise as an anticancer agent. It induces apoptosis, inhibits DNA synthesis in prostate cancer cells, and enhances other treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Cladribine is a known chemotherapeutic agent for lymphoid malignancies and leukemia.
- 2-Chloroadenosine, a related compound, has been less investigated but shows potential anticancer properties.
- Nucleoside analogues, like those derived from 2-Chloroadenosine, are effective antimetabolites in cancer treatment.
Purpose of the Study:
- To review laboratory research proposing a novel role for 2-Chloroadenosine as an anticancer agent.
- To explore the mechanisms of action and potential therapeutic applications of 2-Chloroadenosine.
- To evaluate the combined effects of 2-Chloroadenosine with other anticancer agents.
Main Methods:
- Investigated the effects of 2-Chloroadenosine on human prostate cancer PC3 cells.
- Assessed DNA synthesis inhibition and cell cycle arrest.
- Examined the synergy of 2-Chloroadenosine with Docetaxel.
- Analyzed the modulation of PAR-1 and IL-23 gene expression.
Main Results:
- 2-Chloroadenosine acts as a precursor to an S-phase specific nucleoside analogue in PC3 cells, inhibiting DNA synthesis and causing S-phase accumulation.
- It sensitizes cells to other antineoplastic agents and can be combined with checkpoint disregulators to enhance cytotoxicity.
- In combination with Docetaxel, 2-Chloroadenosine reduced PC3 cell proliferation and invasiveness in vitro.
- Gene expression analysis indicated potential modulation of cancer metastasis and immune activity.
Conclusions:
- 2-Chloroadenosine demonstrates significant anticancer potential, particularly in prostate cancer.
- Its ability to inhibit DNA synthesis and sensitize cells makes it a promising candidate for combination therapies.
- Further research into its mechanisms and therapeutic applications is warranted to establish its role as a novel anticancer agent.
More Related Videos
Related Concept Videos
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...